HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Superior efficacy and tolerance of reduced doses of vemurafenib plus anakinra in Erdheim-Chester disease: Towards the paradigm of combined targeting and immune therapies.

AuthorsFréderic Franconieri, Nicolas Martin-Silva, Hubert de Boysson, Françoise Galateau-Salle, Jean-François Emile, Boris Bienvenu, Achille Aouba
JournalActa oncologica (Stockholm, Sweden) (Acta Oncol) Vol. 55 Issue 7 Pg. 930-2 (Jul 2016) ISSN: 1651-226X [Electronic] England
PMID27031008 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Indoles
  • Interleukin 1 Receptor Antagonist Protein
  • Sulfonamides
  • Vemurafenib
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
Topics
  • Aged
  • Erdheim-Chester Disease (drug therapy, genetics, immunology)
  • Female
  • Hand-Foot Syndrome (etiology)
  • Humans
  • Immunotherapy (methods)
  • Indoles (administration & dosage, adverse effects)
  • Interleukin 1 Receptor Antagonist Protein (administration & dosage)
  • Mutation
  • Proto-Oncogene Proteins B-raf (genetics)
  • Sulfonamides (administration & dosage, adverse effects)
  • Vemurafenib

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: